Novartis AG
NYSENVS cost to borrow surges to 0.73%, up 223% in one week amid rising short demand.
A new long-form analysis for NVS this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNVS reports Q2 results on July 21 with options markets leaning more defensive than usual and short interest building at an unusual pace for a mega-cap pharma name. The options signal is the clearest pre-earnings tell.…
Snapshot as of 15 Aug 2026
Options traders are loading up on puts. Short sellers are adding positions at the fastest weekly pace in months. Yet the borrow market is saying the opposite — availability has loosened, not tightened. That…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVS — free to start on ORTEX.
Sign up for free →Open NVS on ORTEX